GNCA News and Press, Genocea Biosciences Inc. From 04/11/22

What to Know About Trading Penny Stocks on April 11th With another week of trading penny stocks getting off to an interesting start, there is a lot for investors to know. Considering that there is still an extremely high amount of volatility in the stock market, investors need to be on ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time to start off another week of trading with the biggest pre-market stock movers for Monday! Source: Eric Urquhart/Shutterstock.com Clinical trials data, a buyout, a new product announcement, and more ...

GEN-011 shows consistent pattern of activity in first five heavily pre-treated, checkpoint-refractory patients with advanced solid tumors and progressive disease Dose escalation continues toward potentially more effective regimen Initial translational data corroborate clin...

CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced details for a planned investor webinar to coincide with the American Association for Cancer R...

CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at ...

Genocea Biosciences, Inc. (GNCA) Q4 2021 Earnings Conference Call March 10, 2022, 08:30 ET Company Participants Daniel Ferry - LifeSci Advisors William Clark - President, CEO & Director Diantha Duvall - CFO & Secretary Thomas Davis - Chief Medical Officer Jessica Flechtner - Chief Sci...

Genocea Biosciences press release (NASDAQ:GNCA): Q4 GAAP EPS of -$0.19 misses by $0.01. Cash and cash equivalents of $37.1M. The company's existing cash is sufficient to support current operations into Q3 2022, however it has strategic plans to extend operations into 2023. For further detai...

Initial GEN-011 clinical trial data to be presented at AACR Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunoth...

Genocea Biosciences (NASDAQ:GNCA) is scheduled to announce Q4 earnings results on Thursday, Mar. 10, before market open. The consensus EPS estimate is -$0.18 and the consensus revenue estimate is $0.05M. Over the last 2 years, GNCA has beaten EPS estimates 75% of the time and has beaten ...

Company to present late-breaking clinical trial update for TiTAN trial of GEN-011, Genocea’s neoantigen-targeted peripheral T cell therapy for solid tumors The PLANET manufacturing process reliably generates abundant, high-quality neoantigen-specific T cells Preclin...